R&D Parexel: Flawless execution, policy shifts & patient-centric... Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.
Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform
Digital Ten years of innovation at Frontiers Health – Live from Berl... Tune into a wrap-up podcast from Frontiers Health 2025, with Jonah Comstock, Nicole Raleigh, and Jessica DaMassa.
Market Access Unlocking oncology access: What the OECD findings mean for m... New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
R&D FT US Pharma and Biotech Summit: Live coverage This week, pharmaphorum heads to the Big Apple for the FT US Pharma and Biotech Summit, a one-day event where executives from some of the world’s top pharma companies will come together to
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
